Published online: November 15, 2016
House dust mite (HDM) is the most prevalent indoor allergen, and HDM exposure is frequently the cause of allergic respiratory disease, including allergic rhinitis and allergic asthma in HDM sensitized individuals. Allergy immunotherapy is an established treatment option for allergic respiratory diseases caused by e.g. pollens, animal dander, and HDM. Recently, a new class of allergy immunotherapy in the form of fast-dissolving tablets for sublingual administration has emerged, which does not require repeated injections, and is suitable for home-treatment once the first dose is tolerated under medical supervision.
In an original article recently published in The Journal of Allergy & Clinical Immunology (JACI), Okubo and colleagues confirmed that the standardized HDM sublingual immunotherapy tablet (SQ HDM SLIT-tablet) relieved HDM allergic rhinitis symptoms and improved quality of life in more than 900 Japanese patients with allergic rhinitis caused by HDM.
The primary endpoint of the trial comprised allergic rhinitis symptoms and medication use, which were reduced to a clinical meaningful degree. In addition, the number of symptom-free days increased and symptom-severe days decreased, and a significant improvement of the patients' quality of life was observed. The trial included both adults and adolescents, and the clinical benefits of the treatment was the same in the two age groups. The treatment was well tolerated.
In addition to the current trial, the clinical efficacy and safety of the SQ HDM SLIT-tablet has been confirmed in large trials in Europe (adults) and North America (adults and adolescents), which demonstrates the relevance and robustness of the treatment in ethnically diverse populations, and sets the highest standard for evidence-based HDM allergy immunotherapy.
The Journal of Allergy and Clinical Immunology (JACI) is the official scientific journal of the AAAAI, and is the most-cited journal in the field of allergy and clinical immunology.